Humacyte, Inc. (HUMA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.40-12.11%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · HUMA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 98.2% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
HUMA — earnings miss
Dated 2026-08-12
Results of Operations and Financial Condition On August 12, 2026, Humacyte, Inc. issued a press release regarding its financial results for its fiscal second quarter ended June 30, 2026. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information contained herein, including the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended…
Why it matters: Starting the study would move CTEV from early testing toward human data. Humacyte planned to start it in Q3 2026.
Supportive ifHumacyte reports that the CTEV Phase 2a CABG study began and enrolled its first patient.
Worry ifHumacyte reports no study start or first patient by the November 11 earnings report.
Why it matters: FDA acceptance would let the review move ahead. A refusal or request for major new data could slow the path to a dialysis use.
Watch forThe FDA accepts the dialysis ATEV filing for review without a request for major new data.
Also watch forThe FDA refuses to review the filing or requests major new data before review.
Why it matters: Sales rose from $0.1 million to $0.4 million year over year in Q2. The next report tests whether hospital use keeps growing.
Supportive ifOn November 11, Q3 Symvess sales top $0.4 million, and the company reports use at more hospitals.
Worry ifOn November 11, Q3 Symvess sales are $0.4 million or less, or the company reports less use at hospitals.
Why it matters: The company had notices tied to a share price below $1.00. A compliance update would show whether this listing issue is resolved.
Watch forHumacyte says Nasdaq confirmed it meets the $1.00 bid-price rule.
Also watch forHumacyte reports a missed deadline, a new Nasdaq notice, or action to delist it.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$324 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $1,030 loss on $10,000 · 10.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,623 loss on $10,000 · 76.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.